Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Improves EFS and OS in Cisplatin-Eligible Patients with Muscle Invasive Bladder Cancer By Ogkologos - November 18, 2024 922 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NIAGARA study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Disease in a dish: Mini-gut organoids and the challenges of bowel... February 11, 2022 Genetic Signature May Help Tailor Treatment for Meningioma December 21, 2023 This Common Antibiotic May Help Support Immune System in Cancer Patients... December 12, 2019 Clinical Benefit and Safety of Encorafenib Plus Binimetinib in Treatment-Naïve and... June 12, 2023 Load more HOT NEWS The IGCCCG Update Model Allows Improved and More Granular Individual Prognostic... ESMO Asia Congress 2022, 2-4 December 2022 Research shows one size doesn’t fit all for cervical screening in... EMA Recommends Extension of Indications for Blinatumomab
